Evidence map›Paper›PMID 26150809›Full record

ArticleFrontiers in microbiology2015

Antimicrobial nisin acts against saliva derived multi-species biofilms without cytotoxicity to human oral cells.

Jae M Shin, Islam Ateia, Jefrey R Paulus, Hongrui Liu, J Christopher Fenno, Alexander H Rickard, Yvonne L Kapila

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 137 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. A gut-derivedmBio · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Addition of nisin to high-viscosity glass-ionomer cement: a comparative in vitro study on antibacterial and physical properties.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jae M ShinDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor MI, USA.
Islam AteiaDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor MI, USA.
Jefrey R PaulusDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor MI, USA.
Hongrui LiuDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor MI, USA.
J Christopher FennoDepartment of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor MI, USA.
Alexander H RickardDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor MI, USA.
Yvonne L KapilaDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor MI, USA.
University of Michigan–Ann Arbor · US

Funding

Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
NIDCR NIH HHS T32 DE007057
6 · The paper itself

Abstract

objectivesNisin is a lantibiotic widely used for the preservation of food and beverages. Recently, investigators have reported that nisin may have clinical applications for treating bacterial infections. The aim of this study was to investigate the effects of ultra pure food grade Nisin ZP (>95% purity) on taxonomically diverse bacteria common to the human oral cavity and saliva derived multi-species oral biofilms, and to discern the toxicity of nisin against human cells relevant to the oral cavity.

methodsThe minimum inhibitory concentrations and minimum bactericidal concentrations of taxonomically distinct oral bacteria were determined using agar and broth dilution methods. To assess the effects of nisin on biofilms, two model systems were utilized: a static and a controlled flow microfluidic system. Biofilms were inoculated with pooled human saliva and fed filter-sterilized saliva for 20-22 h at 37°C. Nisin effects on cellular apoptosis and proliferation were evaluated using acridine orange/ethidium bromide fluorescent nuclear staining and lactate dehydrogenase activity assays.

resultsNisin inhibited planktonic growth of oral bacteria at low concentrations (2.5-50 μg/ml). Nisin also retarded development of multi-species biofilms at concentrations ≥1 μg/ml. Specifically, under biofilm model conditions, nisin interfered with biofilm development and reduced biofilm biomass and thickness in a dose-dependent manner. The treatment of pre-formed biofilms with nisin resulted in dose- and time-dependent disruption of the biofilm architecture along with decreased bacterial viability. Human cells relevant to the oral cavity were unaffected by the treatment of nisin at anti-biofilm concentrations and showed no signs of apoptotic changes unless treated with much higher concentrations (>200 μg/ml).

conclusionThis work highlights the potential therapeutic value of high purity food grade nisin to inhibit the growth of oral bacteria and the development of biofilms relevant to oral diseases.

Indexed as

apoptosisconfocaldental plaquehuman oral cellsnisinoral diseasessaliva derived multi-species biofilms

Identifiers

PMID26150809
PMCPMC4471743
OpenAlexW1532610717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.